Ding YF - Search Results

1

Increased risk of myocardial infarction with dabigatran etexilate: fact or fiction? A critical meta-analysis of over 580,000 patients from integrating randomized controlled trials and real-world studies.

Wei AH, Gu ZC, Zhang C, Ding YF, Liu D, Li J, Liu XY, Lin HW, Pu J. Wei AH, et al. Among authors: ding yf. Int J Cardiol. 2018 Sep 15;267:1-7. doi: 10.1016/j.ijcard.2018.05.048. Epub 2018 May 18. Int J Cardiol. 2018. PMID: 29801762

2

Multiple beneficial outcomes of medication therapy management interventions in randomized control trials and non-randomized control trials: A protocol for systematic review and meta-analysis.

Deng ZJ, Ding YF, Peng SS, Wang L, Wei AH. Deng ZJ, et al. Among authors: ding yf. Medicine (Baltimore). 2022 Oct 28;101(43):e31491. doi: 10.1097/MD.0000000000031491. Medicine (Baltimore). 2022. PMID: 36316852 Free PMC article.

3

Clinical, economic and humanistic outcomes of medication therapy management services: A systematic review and meta-analysis.

Deng ZJ, Gui L, Chen J, Peng SS, Ding YF, Wei AH. Deng ZJ, et al. Among authors: ding yf. Front Pharmacol. 2023 Apr 5;14:1143444. doi: 10.3389/fphar.2023.1143444. eCollection 2023. Front Pharmacol. 2023. PMID: 37089963 Free PMC article.

4

Perceptions of Generic Drugs in the Pharmacists of Public Hospitals: A Cross-sectional Survey in Hubei Province of China.

Li WJ, Xia MJ, Gong SW, Ding YF. Li WJ, et al. Among authors: ding yf. Curr Med Sci. 2021 Oct;41(5):987-995. doi: 10.1007/s11596-021-2412-4. Epub 2021 Sep 2. Curr Med Sci. 2021. PMID: 34476663

5

A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.

Shu Y, Ding Y, Dai B, Zhang Q. Shu Y, et al. Expert Opin Drug Saf. 2022 Apr;21(4):563-572. doi: 10.1080/14740338.2022.2016696. Epub 2021 Dec 31. Expert Opin Drug Saf. 2022. PMID: 34918584

6

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system.

Shu Y, He X, Wu P, Liu Y, Ding Y, Zhang Q. Shu Y, et al. Front Public Health. 2022 Oct 20;10:996179. doi: 10.3389/fpubh.2022.996179. eCollection 2022. Front Public Health. 2022. PMID: 36339230 Free PMC article.

7

Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma.

Shu Y, Tang Y, Ding Y, Zhang Q. Shu Y, et al. Int Immunopharmacol. 2023 Sep;122:110543. doi: 10.1016/j.intimp.2023.110543. Epub 2023 Jul 3. Int Immunopharmacol. 2023. PMID: 37406395 Free article.

8

Ethyl Acetate Extracts of Semen Impatientis Inhibit Proliferation and Induce Apoptosis of Human Prostate Cancer Cell Lines through AKT/ERK Pathways.

Wang T, Cai Y, Song W, Chen R, Hu D, Ye J, Liu L, Peng W, Zhang J, Wang S, Yang W, Liu J, Ding Y. Wang T, et al. Biomed Res Int. 2017;2017:1243515. doi: 10.1155/2017/1243515. Epub 2017 Mar 13. Biomed Res Int. 2017. PMID: 28386546 Free PMC article.

9

Hematological toxicities in PARP inhibitors: A real-world study using FDA adverse event reporting system (FAERS) database.

Shu Y, Ding Y, He X, Liu Y, Wu P, Zhang Q. Shu Y, et al. Cancer Med. 2023 Feb;12(3):3365-3375. doi: 10.1002/cam4.5062. Epub 2022 Jul 24. Cancer Med. 2023. PMID: 35871395 Free PMC article.

10

Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China.

Shu Y, Ding Y, Zhang Q. Shu Y, et al. Front Oncol. 2022 Apr 20;12:851522. doi: 10.3389/fonc.2022.851522. eCollection 2022. Front Oncol. 2022. PMID: 35515123 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

217 results

Search Page

Filters